Virtual 2021 BioHealth Capital Region Forum

Top 3 by 2023

September 13-14, 2021 Two Half-Days


This event is free for executive-level biotech leaders and is organized by the following event partners – Association of University Research Parks, AstraZeneca, BioHealth Innovation, BRAINBox Solutions, Inc, Children’s National Hospital, Emergent BioSolutions, George Mason University, Johnson & Johnson Innovation – JLABS @ Washington, DC, Maryland Department of Commerce, and Virginia Bio.

NOTE: Your registration for this event also enables you to view the 2021 BioHealth Capital Region Crab Trap Competition

taking place on September 29, 2021

2021 Agenda

Agenda Subject To Updates

8:30 AM – Welcoming Remarks

  • Rich Bendis, President and CEO, BioHealth Innovation, Inc.
  • Daniel Carey M.D., Secretary of Health and Human Services, Commonwealth of Virginia
  • Marc Elrich, County Executive, Montgomery County, MD
  • Kelly Schulz, Secretary, Maryland Department of Commerce

9:05 AM – State of the BioHealth Capital Region Address and Introduction

  • Rich Bendis, President and CEO, BioHealth Innovations, Inc.

9:20 AM – GEN Top 10 BioPharma Clusters Update

  • Alex Philippidis, Senior News Editor, Genetic Engineering & Biotechnology News
  • Pete Briskman, Executive Managing Directors and Co-Lead, JLL

10:10 AM – Keynote (Introduction by Julie Lenzer, Chief Innovation Officer, University of Maryland)

  • Chris Monroe – CEO & Co-Founder, IonQ, Inc.

Bio Byte Segment

  • Hartaj Singh, Managing Director and Senior Analyst, Oppenheimer & Co. Inc.

10:55 AM – Biomedical Big Data: How to Get Real Smarts in a World Full of Artificial Intelligence

  • Eric Stahlberg, MD, Director, Biomedical Informatics and Data Science, Frederick National Laboratory for Cancer Research (MODERATOR)
  • David Ennist, PhD, CEO, Origent Data Sciences, Inc.
  • Vin Singh, MBA, Founder & CEO, BullFrog AI
  • Ellington West, CEO, Sonavi Labs

Bio Byte Segment

  • Ellen Ambrose, Director of AI, Protenus

11:45 AM – IP Analysis and Protection

  • Donna Edmonds, CEO, BRAINBOX Solutions Inc. (MODERATOR)
  • Reid Adler, Co-Managing Partner, Capital Technology Law Group, LLC
  • Charlie Andres, Shareholder, Greenberg Trauig
  • Kolaleh Eskandanian, Vice President & Chief Innovation Officer, Children’s National Hospital

Bio Byte Segment

  • Kurt Newman, President and CEO, Children’s National

12:40 PM – Federal Funding for Bio Research and Commercialization: What’s New and What’s on Tap

  • Brian Darmody, CEO, Association of University Research Parks (AURP) (Moderator)
  • Senator Chris Van Hollen, United States Senator from the State of Maryland (Opening Statement)
  • Leslee K. Gilbert, Vice President, Van Scoyoc Associates
  • Matt McMahon, PhD, Director, Seed, Office of Extramural Research, National Institutes of Health (NIH)
  • Justin Yang, Catalyst Office Director, BARDA

1:30 PM – FireSide Chat with Phlow: Data at Work in Advanced Pharmaceutical Manufacturing

  • John Newby, CEO, Virginia Biotechnology Association (Moderator)
  • Eric Edwards, Co-Founder & CEO, Phlow
  • Frank Gupton, Co-Founder, Phlow

2:05 PM – Closing of Day 1

  • Rich Bendis, President and CEO, BioHealth Innovations, Inc.


Structured Networking

Agenda Subject To Updates

9:00 AM – Fireside Chat with Dr. Anthony Fauci

  • Rich Bendis, President and CEO, BioHealth Innovations, Inc. (Moderator)
  • Anthony Fauci, MD, Director, U.S. National Institute of Allergy and Infectious Diseases

9:35 AM – Infectious Diseases and The Global Pandemic Center

  • Stu Solomon, President & CEO, Connected DMV (Moderator)
  • Nahid Bhadelia, Founding Director, Boston University Center for Emerging Infectious Diseases Policy & Research (CEID)
  • James Crowe, MD, Director, Vanderbilt Vaccine Center, Vanderbilt University Medical Center
  • Andy Weber, Independent Consultant and Senior Fellow, Council on Strategic Risks

Bio Byte Segment

  • James Crowe, MD, Director, Vanderbilt Vaccine Center, Vanderbilt University Medical Center
  • Thomas Haag, Co-Founder and CEO, AexeRNA Therapeutics

10:30 AM – Developing and Retaining Talent – Keeping the Best and Brightest in the BHCR

  • Joe Sanchez, PhD, MBA, Director, R&D Science Engagement, AztraZeneca (Moderator)
  • Christine Dingivan, President & CEO, Emmes
  • JB Holston, CEO, Greater Washington Partnership
  • James Hughes, Senior Vice President, University of Maryland, Baltimore

Bio Byte Segment

  • Dr. Amrie Grammer, Co-Founder and COO/CSO, AMPEL BioSolutions

11:20 AM – Real Estate and Resources in the BHCR

  • Amy Adams, Executive Director, George Mason University Institute for Biohealth Innovation (Moderator)
  • Matt Brady, Senior Vice President, Scheer Partners
  • James Matan, Director of Progress Labs, Matan, Inc.
  • John Newby, CEO, Virginia Biotechnology Association

12:10 PM – Venture Capital Update (Introduction by Rich Bendis, President and CEO, BioHealth Innovations, Inc.)

  • Joel Marcus, Executive Chairman and Founder, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments

Bio Byte Segment

  • Sally Allain, Head, JLABS @ Washington DC – Johnson & Johnson Innovation

12:45 PM – White House OSTP Discussion on ARPA-H

  • Tara Schwetz, Assistant Director for Biomedical Science Initiatives, White House Office of Science and Technology Policy (OSTP)
  • Rich Bendis, President and CEO, BioHealth Innovations, Inc.

1:20 PM – Closing Remarks

  • Rich Bendis, President and CEO, BioHealth Innovations, Inc.

Structured Networking


Hubly Surgical is a cranial drill fixing the most common neurosurgery’s exorbitant failure rate. They have built a next-gen cranial drill designed for safety and ease of use in a $4B market ripe to be overtaken. With plunge prevention and catheter guidance, the Hubly Drill does not require a heavy FDA approval process as a Class II 510(k). They have grants from the National Science Foundation and are partnered with Northwestern Hospital.

Linshom is first to deliver an Operating Room quality respiratory profile to the patient bedside for continuous, predictive respiratory monitoring. Their FDA cleared device provides a predictive (vs. responsive) respiratory profile including Respiratory Rate (RR), Tidal Volume (TV), Minute Ventilation (MV), Inspiratory-Expiratory ratio (I/E) and Apnea detection that are all delivered continuously and in real time. Current technology is too large, complex and expensive. They solve the fundamental disconnect between current standard of care and patient needs for continuous respiratory monitoring.

Nanochon is developing an implantable device, based on 3D printing and a synthetic material, which supports and regenerates surface cartilage damage in the knee. The device is also off the shelf and cost effective, compared to the current alternatives to knee replacement.”

Relavo is changing the way that kidney failure patients receive treatment by making home dialysis safer and more accessible. Peritoneal dialysis is a form of home treatment that offers patients better health outcomes and higher satisfaction. However, it is severely underutilized due to the risk of infection. We are addressing this with the PeritoneX — a self-disinfecting connection device that aims to reduce infection-risk and enable more patients to receive quality care at home.

Value and Trust Co. Ltd (VNTC) is a medical device company, which treats scoliosis in a patient-friendly way that encourages maximum compliance. Comprised of a customized dynamic brace that doesn’t require traditional hard plaster fitting, the Spinamic system includes pressure sensing, pressure adjustment, and real-time tracking of data.

Previous Crab Trap Winners

2020 – BrainScope
BrainScope is a developer of a non-invasive medical device intended to objectively assess head-injured patients for both brain bleeds & concussions at point of care. The company’s device is FDA-cleared, portable, EEG-based, assessment tool that empowers physicians to quickly triage patients for brain bleeds, concussion and the need for a CT scan, providing healthcare professionals with objective diagnostic insights that enable better patient care. The company is reportedly in the process of raising $15 million of venture funding on March 25, 2021. The funds will be used to speed up and expand the company’s commercial execution. Previously, The company was approved for a Paycheck Protection Program Loan for $1.07 million from Sandy Spring Bank on April 09, 2020. The application cited 40 jobs to be retained with the financing.
2019 – Floreo Inc.
Floreo is a developer of a learning platform designed to build a new generation of training program for people with autism and other developmental challenges. The company’s platform leverages the power of virtual reality to develop a supplementary method of teaching social and communication skills, enabling individuals with an autism spectrum disorder to build real-world skills. The company was approved for a Paycheck Protection Program Loan in the range of $150,000-350,000 from Wells Fargo Bank, National Association on May 3, 2020. The application cited jobs to be retained with the financing.
2018 – Galen Robotics
Galen Robotics, is a developer of a surgical robot designed to aid surgeons across several disciplines with minimal disturbance to existing workflows. The company’s robot is designed to assist doctors in executing precise movements with certain surgical instruments, while reducing risks from hand shakiness, enabling surgeons to make minimally invasive interventions safer, faster and more precise. The company is reportedly seeking $25 million of Series A venture funding from undisclosed investors as of March 19, 2021. Previously, the company raised $7 million of seed funding from Verte Capital, TEDCO and Maryland Department of Commerce on November 6, 2020.
2017 – LifeSprout
LifeSprout is a Developer of synthetic soft tissue substitutes intended to be used for aesthetic and reconstructive medicine in tissue reproduction. The company’s tissue substitutes focus on regrowth human tissue by transferring tissue from one part of the body to another, enabling doctors to repair patients’ soft tissue damage from trauma, natural aging, surgery, cancer and metabolic disease.
2016 –  Sonavex

Sonavex, a medical device company intended to create novel and automated ultrasound technology. The company has developed a portfolio of novel ultrasound solutions to visualize and quantify critical clinical data for improved outcomes and reduced costs in new surgical applications, empowering clinicians with actionable data to deliver superior patient care and deliver savings to the healthcare system.